By continuing, you agree to the Terms of Service.
This website uses cookies to enhance your browsing experience. Learn More.
Essential Cookies
Optional Cookies
Login
Logo for company Candel Therapeutics, Inc.

Candel Therapeutics, Inc. (CADL)

NASDAQ Currency in USD
$26.00
-$0.16
-0.61%
Last Update: 18 Jul 2026, 14:21
$1.38bn
Market Cap
-26.45
P/E Ratio (TTM)
Forward Dividend Yield
$17.66-$34.87
52 Week Range

CADL Stock Price Chart

Explore Candel Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze CADL price movements and trends.

CADL Company Profile

Discover essential business fundamentals and corporate details for Candel Therapeutics, Inc. (CADL) to support your stock research and investment decisions.

Sector

Healthcare

Industry

Biotechnology

IPO Date

27 Jul 2021

Employees

38.00

CEO

Paul-Peter Tak

Description

Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma. Furthermore, the company is advancing CAN-3110, an investigational therapy currently in Phase I clinical trials for recurrent glioblastoma. Established in 2003, the company operated as Advantagene, Inc. until November 2020, when it rebranded as Candel Therapeutics, Inc.

CADL Financial Timeline

Browse a chronological timeline of Candel Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.

Upcoming earnings on 13 Aug 2026

EPS estimate is -$0.22.

Earnings released on 14 May 2026

EPS came in at -$0.14 surpassing the estimated -$0.22 by +36.36%.

Earnings released on 12 Mar 2026

EPS came in at -$0.54 falling short of the estimated -$0.24 by -125.00%.

Earnings released on 13 Nov 2025

EPS came in at -$0.21 falling short of the estimated -$0.17 by -23.53%.

Earnings released on 14 Aug 2025

EPS came in at -$0.09 surpassing the estimated -$0.17 by +47.06%.

Earnings released on 13 May 2025

EPS came in at $0.13 surpassing the estimated -$0.24 by +154.17%.

Earnings released on 13 Mar 2025

EPS came in at -$0.40 falling short of the estimated -$0.23 by -73.91%.

Earnings released on 14 Nov 2024

EPS came in at -$0.33 .

Earnings released on 13 Aug 2024

EPS came in at -$0.74 .

Earnings released on 14 May 2024

EPS came in at -$0.28 .

Earnings released on 28 Mar 2024

EPS came in at -$0.38 falling short of the estimated -$0.16 by -137.50%, while revenue for the quarter reached $1.78m .

Earnings released on 9 Nov 2023

EPS came in at -$0.29 falling short of the estimated -$0.19 by -52.63%.

Earnings released on 10 Aug 2023

EPS came in at -$0.33 falling short of the estimated -$0.23 by -43.48%.

Earnings released on 11 May 2023

EPS came in at -$0.30 surpassing the estimated -$0.35 by +14.29%.

Earnings released on 30 Mar 2023

EPS came in at -$0.18 falling short of the estimated -$0.16 by -12.50%, while revenue for the quarter reached $31.00k , beating expectations by +138.46%.

Earnings released on 10 Nov 2022

EPS came in at -$0.30 surpassing the estimated -$0.53 by +43.40%, while revenue for the quarter reached $31.00k , beating expectations by +100.00%.

Earnings released on 5 Aug 2022

EPS came in at -$0.14 surpassing the estimated -$0.54 by +74.07%, while revenue for the quarter reached $31.00k .

Earnings released on 12 May 2022

EPS came in at -$0.03 surpassing the estimated -$0.49 by +93.88%, while revenue for the quarter reached $31.00k , beating expectations by +50.00%.

Earnings released on 29 Mar 2022

EPS came in at $0.05 surpassing the estimated -$0.32 by +115.63%, while revenue for the quarter reached $31.00k , beating expectations by +106.67%.

Earnings released on 12 Nov 2021

EPS came in at -$0.34 falling short of the estimated -$0.27 by -25.93%, while revenue for the quarter reached $31.00k , beating expectations by +35.01%.

Earnings released on 8 Sept 2021

EPS came in at -$0.31 falling short of the estimated -$0.12 by -158.33%, while revenue for the quarter reached $31.00k .

Earnings released on 28 Jul 2021

EPS came in at -$0.24 , while revenue for the quarter reached $31.00k .

CADL Stock Performance

Access detailed CADL performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.

Explore Related Stocks

Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.

Discover More
Command Palette
Search for a command to run